Compare Nasdaq Inc (NDAQ) vs Nuvalent Inc (NUVL) Price & Performance

Nasdaq IncTrade

Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Nasdaq Inc vs Nuvalent Inc — how do they compare? Nasdaq Inc trades at $90.25 (market cap $51.96B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nasdaq Inc is far larger — about 5.3× Nuvalent Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

	NDAQ	NUVL
Market Cap	$51.96B	$9.81B
Sector	Financials	Technology
52-Week High	$100.98	$123.96
52-Week Low	$76.85	$72.16
Enterprise Value	$59.02B	$8.52B
Dividend Yield	1.22%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NDAQ

US stock indices bounce on technical support amid earnings season uncertainty.FXEmpire · 12 hours agoNeutral Nasdaq Private Market acquires Nasdaq Fund Secondaries to expand private market liquidity platform.GlobeNewsWire · 12 hours agoBullish Georgia's top 5 banks adopt Nasdaq Calypso platform to modernize treasury infrastructure.GlobeNewsWire · 1 day agoBullish View details →

NUVL

Brodsky & Smith investigates fiduciary duty breaches in multiple major merger deals.GlobeNewsWire · 10 hours agoBearish View details →

About Nasdaq Inc

Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.